Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy
NCT ID: NCT00634491
Last Updated: 2008-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2007-09-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine
NCT00353340
N-Acetyl Cystein and Contrast Nephropathy
NCT01820195
Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
NCT02088502
Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease
NCT00808795
Perioperative Use of NAC to Prevent AKI in Patients With Pre-existing Moderate Renal Insufficiency Following Cardiac Surgery
NCT05555511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
sodium bicarbonate
150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
2
Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
Acetazolamide
Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
3
normal salin 1cc/kg/hr before and after angiography
normal salin
1 cc/kg/hr 6 hour before and after angiography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sodium bicarbonate
150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
Acetazolamide
Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
normal salin
1 cc/kg/hr 6 hour before and after angiography
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* electrolyte and acid-base imbalance
* pulmonary edema
* allergy to Acetazolamide
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fars Heart Foundation
UNKNOWN
Shiraz University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiraz University of Medical Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maryam Pakfetrat, MD
Role: STUDY_CHAIR
Shiraz nephro-urology research center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fars Heart Foundation , Kowsar hospital
Shiraz, , Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatr Cardiol. 2006 Mar-Apr;27(2):238-42. doi: 10.1007/s00246-005-1132-z.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2438
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.